TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05341388

Intervention type: DIAGNOSTIC_TEST
Intervention: MOCA cognitive evaluation test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.

Intervention type: DIAGNOSTIC_TEST
Intervention: MOCA cognitive evaluation test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.

Intervention type: DIAGNOSTIC_TEST
Intervention: BDNF levels
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.

Intervention type: DIAGNOSTIC_TEST
Intervention: BDNF levels
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.

Intervention type: OTHER
Intervention: SF-36 test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.

Intervention type: OTHER
Intervention: SF-36 test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.

Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric depression test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.

Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric depression test
Description: Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
Study: NCT05171855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Description: Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
Study: NCT06569719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy
Description: Includes manual lymphatic drainage (MLD), compression therapy (which consists of compression bandages, compression sleeves, or other types of compression garments), skin care, and lymph-reducing exercises
Study: NCT05467228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibro-tactile stimulation (VTS)
Description: To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibro-tactile stimulation (VTS)
Description: To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibro-tactile stimulation (VTS)
Description: To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibro-tactile stimulation (VTS)
Description: To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
Study: NCT04993768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-101, 100 mg/day
Description: 100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-101, 200 mg/day
Description: 200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-101, 400 mg/day
Description: 400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
Study: NCT05877365

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Process 21-Day Purification Program
Description: Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
Study: NCT05395416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA+HEC110114
Description: administered orally once daily for 12 weeks
Study: NCT04716712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
Study: NCT05949944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib in combination with CHOP
Description: Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
Study: NCT05395416

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally once daily for 12 weeks
Study: NCT05419739

Intervention type: OTHER
Intervention: Glasgow coma scale
Description: This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
Study: NCT06449703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xultophy®
Description: Xultophy®
Study: NCT06214494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restricted High Intensity Treadmill Training
Description: Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HITT
Description: High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
Study: NCT04842344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R
Description: extracorporeal carbon dioxide removal
Study: NCT04940598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity interval exercise
Description: HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.

Intervention type: OTHER
Group type: OTHER
Intervention: No-exercise control group
Description: No-exercise control group
Study: NCT04841668

Intervention type: DRUG
Intervention: Metformin
Description: Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
Study: NCT04374903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ & AZ vs HCQ+SIR
Description: Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ & AZ vs HCQ+SIR
Description: Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
Study: NCT05187338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab +pembrolizumab +durvalumab
Description: This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks.
Study: NCT06340555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GUIA ATENCION MULTIDISCIPLINAR SANT BOI
Description: Women with losses attended according to the multidisciplinary intervention proposed at the SJD Hospital de Sant Boi

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USUAL CARE
Description: Women with losses treated at the Hospital Comarcal del l'Alt Penedes.
Study: NCT04816396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reminiscence Therapy
Description: Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
Study: NCT06287216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Hygiene
Description: Mental hygiene are daily evidence based practices that support mental wellbeing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Care
Description: Instructed to do 10 minutes of self-care daily.
Study: NCT04544618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality operating room simulation
Description: The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
Study: NCT04716712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching identical placebo in packaging, appearance, and taste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching identical placebo in packaging, appearance, and taste.
Study: NCT04883164

Intervention type: OTHER
Intervention: Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
Description: Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.

Intervention type: OTHER
Intervention: Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
Description: Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
Study: NCT05138796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral capsules)
Description: TP-05 (lotilaner oral capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral capsules)
Description: TP-05 (lotilaner oral capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral capsules)
Description: TP-05 (lotilaner oral capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match TP-05 (lotilaner oral capsules)
Study: NCT05993234

Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC.
Study: NCT05138796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match TP-05 (lotilaner oral capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match TP-05 (lotilaner oral capsules)
Study: NCT06433050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sotagliflozin
Description: Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.
Study: NCT05792436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-min interval oscillometric method
Description: Before induction of anesthesia, 20-gauge catheter is inserted to radial artery after local anesthesia with lidocaine, and continuous blood pressure monitoring is started. Anesthesia is induced using propofol, opioids (fentanyl or remifentanil), and neuromuscular relaxants (rocuronium, cisatracurium, or vecuronium). For maintenance of anesthesia, propofol infusion or inhalation anesthetics (sevoflurane or desflurane) are used.~From the start of anesthesia induction to 15 minutes after, arterial blood pressure is monitored at 1-min interval using oscillometric method. The display of continuous arterial pressure on the anesthesia monitor is turned off during the 15-min study period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial catheterization method
Description: During the same time window for 1-min interval oscillometric method, arterial blood pressure is monitored using continuous blood pressure monitoring.
Study: NCT05719220

Intervention type: BEHAVIORAL
Intervention: Group preoperative pelvic floor training
Description: Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
Study: NCT05552729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
Study: NCT05879315

Intervention type: OTHER
Group type: OTHER
Intervention: Fall risk prevention in hospital
Description: All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
Study: NCT04982549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/ Paclitaxel
Description: Carboplatin /Paclitaxel, as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Cisplatin
Description: Pemetrexed / Cisplatin, as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Carboplatin
Description: Pemetrexed / Carboplatin , as per standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
Study: NCT05632250

Intervention type: DEVICE
Group type: OTHER
Intervention: ConvaFoam
Description: ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
Study: NCT05970055

Intervention type: PROCEDURE
Intervention: elective surgery
Description: All elective surgical procedures performed under the study period will be included.
Study: NCT04846686

Intervention type: BIOLOGICAL
Intervention: Placenta pathological examination
Description: a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.

Intervention type: BIOLOGICAL
Intervention: Placenta pathological examination
Description: a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
Study: NCT06144060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS -8427
Description: The dose and frequency of administration were adjusted according to the eGFR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS -8427
Description: The dose and frequency of administration were adjusted according to the eGFR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem and Cilastatin Sodium
Description: The dose and frequency of administration were adjusted according to the eGFR .
Study: NCT06144034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder
Description: Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder
Description: Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
Study: NCT05245500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX1719
Description: MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX1719
Description: MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX1719
Description: MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days